Oncology Group

The Oncology Strategy Group (OSG) focuses on maximizing the impact of hematopoietic stem cell transplantation for the treatment of solid tumors and hematologic malignancies. An effort has been made to minimize frontline protocol competition with the Children’s Oncology Group (COG). Thus, studies from the OSG will center on the following areas:

​

• Rare diseases

• Relapsed or poor prognosis cases

• Novel transplant methodology

• Phase I or II drug or drug combination evaluations

​​

It is envisioned that Phase III trials that involve hematopoietic stem cell support will be performed in collaboration with or by the COG. Preceding pilot protocols may be coordinated through the OSG as members of this committee are also members of the COG. To facilitate communication between the two cooperative groups, the OSG Chair and Vice Chair will be part of the COG Cellular Therapy Committee. The OSG Chairs may ask two (or more) OSG members to serve as liaisons between the COG Cellular Therapy Committee to stay up to date on discussions and planned studies through COG as they relate to malignant disease transplants and/or cellular therapies.